Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results https://lnkd.in/e86RwDsT

More from CEO Dr. Steven Quay in this morning's announcement: “Our decision to advance (Z)-endoxifen into a metastatic breast cancer indication underscores our unwavering commitment to developing a best-in-class therapy for women facing this devastating disease. The encouraging clinical data that has been generated to date supports the potential of (Z)-endoxifen to provide a meaningful benefit to patients who have exhausted other treatment options. By pursuing this strategy, we believe we are not only addressing an urgent medical need but also fortifying the path forward for expanding (Z)-endoxifen’s role across the full spectrum of breast cancer prevention and treatment. We look forward to providing future updates as we execute this plan.” Check out the full release here: https://lnkd.in/eEzYf37B #breastcancer #metastatic $ATOS

Atossa Therapeutics, Inc. Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications #breastcancer #metastatic $ATOS https://lnkd.in/eEzYf37B

Based on a report from the American Cancer Society, #InvasiveBreastCancer incidence has been increasing since the mid-2000s--partly attributable to changing risk factors like excess body weight, later age at 1st birth & decreased numbers of childbirth. Learn here: https://lnkd.in/gRvRaBfS

Learn more about - #BreastCancer in African American Women and this The Disproportionate #Burden By Steven C. Quay, MD, PhD - published last week in #TulsaToday https://lnkd.in/eCp8akE5

Despite comparable #breastcancer incidence rates between African American and white women, African American women have a 42% higher mortality rate. Read more from Atossa Therapeutics, Inc. CEO Dr. Quay in Tulsa Today https://lnkd.in/eCp8akE5

Breast Cancer: African American Women in #TulsaToday The Disproportionate Burden of #BreastCancer https://lnkd.in/eCp8akE5

More from yesterday's announcement - Atossa Therapeutics, Inc. Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance #BreastCancerCare "We are incredibly proud of Dr. Cigler’s dedication to advancing breast cancer care and her relentless pursuit of solutions that address health disparities," said Dr. Steven Quay, M.D., Ph.D., FCAP, CEO of Atossa Therapeutics. "Her leadership and expertise in clinical oncology have been invaluable to our board, and this achievement further underscores the national recognition her commitment to improving patient outcomes. Atossa fully supports initiatives that foster innovative and inclusive approaches to breast cancer treatment and survivorship." #breastcancer #biotech #healthdisparities #innovation https://lnkd.in/eGetcAJ9

Atossa Therapeutics, Inc. Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care #breastcancer #cancerprevention https://lnkd.in/eGetcAJ9

Based on a new report from the American Cancer Society #InvasiveBreastCancer incidence has been increasing since the mid-2000s–partly attributable to risk factors like excess body weight, later age at first birth, and decreased numbers of childbirth. Learn more here https://lnkd.in/gsGW_9n8